Literature DB >> 28002555

Contralateral Prophylactic Mastectomy Decisions in a Population-Based Sample of Patients With Early-Stage Breast Cancer.

Reshma Jagsi1, Sarah T Hawley2, Kent A Griffith3, Nancy K Janz4, Allison W Kurian5, Kevin C Ward6, Ann S Hamilton7, Monica Morrow8, Steven J Katz9.   

Abstract

Importance: Contralateral prophylactic mastectomy (CPM) use is increasing among women with unilateral breast cancer, but little is known about treatment decision making or physician interactions in diverse patient populations. Objective: To evaluate patient motivations, knowledge, and decisions, as well as the impact of surgeon recommendations, in a large, diverse sample of patients who underwent recent treatment for breast cancer. Design, Setting, and Participants: A survey was sent to 3631 women with newly diagnosed, unilateral stage 0, I, or II breast cancer between July 2013 and September 2014. Women were identified through the population-based Surveillance Epidemiology and End Results registries of Los Angeles County and Georgia. Data on surgical decisions, motivations for those decisions, and knowledge were included in the analysis. Logistic and multinomial logistic regression of the data were conducted to identify factors associated with (1) CPM vs all other treatments combined, (2) CPM vs unilateral mastectomy (UM), and (3) CPM vs breast-conserving surgery (BCS). Associations between CPM receipt and surgeon recommendations were also evaluated. All statistical models and summary estimates were weighted to be representative of the target population. Main Outcomes and Measures: Receipt of CPM was the primary dependent variable for analysis and was measured by a woman's self-report of her treatment.
Results: Of the 3631 women selected to receive the survey, 2578 (71.0%) responded and 2402 of these respondents who did not have bilateral disease and for whom surgery type was known constituted the final analytic sample. The mean (SD) age was 61.8 (12) years at the time of the survey. Overall, 1301 (43.9%) patients considered CPM (601 [24.8%] considered it very strongly or strongly); only 395 (38.1%) of them knew that CPM does not improve survival for all women with breast cancer. Ultimately, 1466 women (61.6%) received BCS, 508 (21.2%) underwent UM, and 428 (17.3%) received CPM. On multivariable analysis, factors associated with CPM included younger age (per 5-year increase: odds ratio [OR], 0.71; 95% CI, 0.65-0.77), white race (black vs white: OR, 0.50; 95% CI, 0.34-0.74), higher educational level (OR, 1.69; 95% CI, 1.20-2.40), family history (OR, 1.63; 95% CI, 1.22-2.17), and private insurance (Medicaid vs private insurance: OR, 0.47; 95% CI, 0.28-0.79). Among 1569 patients (65.5%) without high genetic risk or an identified mutation, 598 (39.3%) reported a surgeon recommendation against CPM, of whom only 12 (1.9%) underwent CPM, but among the 746 (46.8%) of these women who received no recommendation for or against CPM from a surgeon, 148 (19.0%) underwent CPM. Conclusions and Relevance: Many patients consider CPM, but knowledge about the procedure is low and discussions with surgeons appear to be incomplete. Contralateral prophylactic mastectomy use is substantial among patients without clinical indications but is low when patients report that their surgeon recommended against it. More effective physician-patient communication about CPM is needed to reduce potential overtreatment.

Entities:  

Mesh:

Year:  2017        PMID: 28002555      PMCID: PMC5531287          DOI: 10.1001/jamasurg.2016.4749

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   16.681


  28 in total

1.  Risk, worry and cosmesis in decision-making for contralateral risk-reducing mastectomy: analysis of 60 consecutive cases in a specialist breast unit.

Authors:  H Beesley; C Holcombe; S L Brown; P Salmon
Journal:  Breast       Date:  2012-06-29       Impact factor: 4.380

2.  Variation in Contralateral Prophylactic Mastectomy Rates According to Racial Groups in Young Women with Breast Cancer, 1998 to 2011: A Report from the National Cancer Data Base.

Authors:  Laura Grimmer; Erik Liederbach; Jose Velasco; Catherine Pesce; Chi-Hsiung Wang; Katharine Yao
Journal:  J Am Coll Surg       Date:  2015-04-23       Impact factor: 6.113

3.  Prospective Study of Surgical Decision-making Processes for Contralateral Prophylactic Mastectomy in Women With Breast Cancer.

Authors:  Patricia A Parker; Susan K Peterson; Isabelle Bedrosian; Melissa A Crosby; Yu Shen; Dalliah M Black; Gildy Babiera; Henry M Kuerer; Jun Ying; Wenli Dong; Scott B Cantor; Abenaa M Brewster
Journal:  Ann Surg       Date:  2016-01       Impact factor: 12.969

4.  Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.

Authors:  Mary B Daly; Robert Pilarski; Jennifer E Axilbund; Michael Berry; Saundra S Buys; Beth Crawford; Meagan Farmer; Susan Friedman; Judy E Garber; Seema Khan; Catherine Klein; Wendy Kohlmann; Allison Kurian; Jennifer K Litton; Lisa Madlensky; P Kelly Marcom; Sofia D Merajver; Kenneth Offit; Tuya Pal; Huma Rana; Gwen Reiser; Mark E Robson; Kristen Mahoney Shannon; Elizabeth Swisher; Nicoleta C Voian; Jeffrey N Weitzel; Alison Whelan; Myra J Wick; Georgia L Wiesner; Mary Dwyer; Rashmi Kumar; Susan Darlow
Journal:  J Natl Compr Canc Netw       Date:  2016-02       Impact factor: 11.908

5.  Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007.

Authors:  Katharine Yao; Andrew K Stewart; David J Winchester; David P Winchester
Journal:  Ann Surg Oncol       Date:  2010-05-12       Impact factor: 5.344

6.  Clinical management factors contribute to the decision for contralateral prophylactic mastectomy.

Authors:  Tari A King; Rita Sakr; Sujata Patil; Inga Gurevich; Michelle Stempel; Michelle Sampson; Monica Morrow
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

7.  Declining incidence of contralateral breast cancer in the United States from 1975 to 2006.

Authors:  Hazel B Nichols; Amy Berrington de González; James V Lacey; Philip S Rosenberg; William F Anderson
Journal:  J Clin Oncol       Date:  2011-03-14       Impact factor: 44.544

8.  Trends and variation in use of breast reconstruction in patients with breast cancer undergoing mastectomy in the United States.

Authors:  Reshma Jagsi; Jing Jiang; Adeyiza O Momoh; Amy Alderman; Sharon H Giordano; Thomas A Buchholz; Steven J Kronowitz; Benjamin D Smith
Journal:  J Clin Oncol       Date:  2014-02-18       Impact factor: 44.544

9.  Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution.

Authors:  Natalie B Jones; John Wilson; Linda Kotur; Julie Stephens; William B Farrar; Doreen M Agnese
Journal:  Ann Surg Oncol       Date:  2009-06-09       Impact factor: 5.344

10.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321

View more
  36 in total

1.  Worry in Thyroid Cancer Survivors with a Favorable Prognosis.

Authors:  Maria Papaleontiou; David Reyes-Gastelum; Brittany L Gay; Kevin C Ward; Ann S Hamilton; Sarah T Hawley; Megan R Haymart
Journal:  Thyroid       Date:  2019-07-25       Impact factor: 6.568

2.  The Role of the Health Care Provider in Building Trust Between Patients and Precision Medicine Research Programs.

Authors:  Anitra Persaud; Vence L Bonham
Journal:  Am J Bioeth       Date:  2018-04       Impact factor: 11.229

3.  Discussions about contralateral prophylactic mastectomy among surgical oncology providers and women with sporadic breast cancer: a content analysis.

Authors:  Thomas A D'Agostino; Abenaa M Brewster; Susan K Peterson; Isabelle Bedrosian; Patricia A Parker
Journal:  Transl Behav Med       Date:  2020-05-20       Impact factor: 3.046

Review 4.  Contralateral prophylactic mastectomy in breast cancer: what to discuss with patients.

Authors:  Giacomo Montagna; Monica Morrow
Journal:  Expert Rev Anticancer Ther       Date:  2020-02-28       Impact factor: 4.512

5.  Temporal trends and regional variation in the utilization of low-value breast cancer care: has the Choosing Wisely campaign made a difference?

Authors:  Joan M Neuner; Ann B Nattinger; Tina Yen; Emily McGinley; Michael Nattinger; Liliana E Pezzin
Journal:  Breast Cancer Res Treat       Date:  2019-04-10       Impact factor: 4.872

6.  Improving Breast Cancer Surgical Treatment Decision Making: The iCanDecide Randomized Clinical Trial.

Authors:  Sarah T Hawley; Yun Li; Lawrence C An; Kenneth Resnicow; Nancy K Janz; Michael S Sabel; Kevin C Ward; Angela Fagerlin; Monica Morrow; Reshma Jagsi; Timothy P Hofer; Steven J Katz
Journal:  J Clin Oncol       Date:  2018-01-24       Impact factor: 44.544

7.  Predictors of genetic testing uptake in newly diagnosed breast cancer patients.

Authors:  Mary K Ladd; Beth N Peshkin; Claudine Isaacs; Gillian Hooker; Shawna Willey; Heiddis Valdimarsdottir; Tiffani DeMarco; Suzanne O'Neill; Savannah Binion; Marc D Schwartz
Journal:  J Surg Oncol       Date:  2020-04-28       Impact factor: 3.454

8.  Breast Cancer Knowledge and Decisions Made for Contralateral Prophylactic Mastectomy: A Survey of Surgeons and Women in the General Population.

Authors:  Rachel C Hooper; Jessica Hsu; Anthony Duncan; Jessica M Bensenhaver; Lisa A Newman; Kelly M Kidwell; Kevin C Chung; Adeyiza O Momoh
Journal:  Plast Reconstr Surg       Date:  2019-05       Impact factor: 4.730

9.  Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.

Authors:  Allison W Kurian; Kevin C Ward; Ann S Hamilton; Dennis M Deapen; Paul Abrahamse; Irina Bondarenko; Yun Li; Sarah T Hawley; Monica Morrow; Reshma Jagsi; Steven J Katz
Journal:  JAMA Oncol       Date:  2018-08-01       Impact factor: 31.777

10.  B-Sure: a randomized pilot trial of an interactive web-based decision support aid versus usual care in average-risk breast cancer patients considering contralateral prophylactic mastectomy.

Authors:  Sharon L Manne; Barbara L Smith; Sara Frederick; Anna Mitarotondo; Deborah A Kashy; Laurie J Kirstein
Journal:  Transl Behav Med       Date:  2020-05-20       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.